The Filing Desk

Angiodynamics vs Inogen

Angiodynamics ANGO · Inogen INGN · Health Care Equipment

Inogen reported revenue of $349 million in fiscal 2025, about the same as Angiodynamics' $320 million in fiscal 2026. Angiodynamics' revenue grew 9.5% in its latest year, and Inogen's grew 3.9%. Angiodynamics had an operating margin of -12.5%, against -8.7% at Inogen. Free cash flow was $1 million at Angiodynamics and −$14 million at Inogen. Their fiscal years end in different months (May 31 and December 31), so the periods don't line up exactly.

Side by side

AngiodynamicsInogen
Latest fiscal yearFY2026, May 31, 2026FY2025, Dec 31, 2025
Revenue$320M$349M
Revenue growth9.5%3.9%
Revenue growth a year, last 5 years1.9%2.5%
Gross margin54.6%44.2%
Operating margin−12.5%−8.7%
Net margin−11.5%−6.5%
Free cash flow$1M−$14M
Free cash flow margin0.2%−3.9%
Return on capital−24.6%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.6%12.5%
Last close$10.76$5.42
P/E at the last close——
Insider trades, last 12 monthssold $344,006sold $142,519
Piotroski F-score4 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AngiodynamicsInogen
Operating margin
Percent of revenue
AngiodynamicsInogen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AngiodynamicsInogen

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Angiodynamics and Inogen pages.